생체흡수성 스텐트 시장 보고서 : 생체 재료별, 흡수율별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global bioabsorbable stents market size reached USD 438.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 786.5 Million by 2033, exhibiting a growth rate (CAGR) of 6.72% during 2025-2033.

Bioabsorbable stents (BRS) are coated with an antiproliferative drug or gene that dissolves over time to restore vessel patency and permit remodeling while retaining recoil. It helps in regulating blood flow at branch points and limiting the amount of blood to areas of the vascular network while maintaining the flow at low perfusion. It also improves lesion imaging with cardiac computed tomography (CT) and magnetic resonance imaging (MRI). In addition, it leaves no residual scaffold, reduces vessel irritation and inflammation, and facilitates repeat treatments to the same site. As a result, BRS finds extensive applications in hospitals and cardiac centers across the globe.

Bioabsorbable Stents Market Trends:

The growing prevalence of cardiovascular diseases due to an unhealthy diet, physical inactivity, and excessive consumption of tobacco and alcohol represents one of the factors driving the market. Moreover, there is a rise in the utilization of percutaneous coronary intervention (PCI) procedures to open a blocked artery for carrying oxygen-rich blood through the body. This, along with the expanding healthcare industry, is contributing to the growth of the market. Besides this, the increasing awareness among the masses about the benefits of bioabsorbable stents is offering lucrative growth opportunities to industry investors. In addition, the growing demand for minimally invasive procedures due to less postoperative pain, fewer operative and postoperative complications, shortened hospital stay, and faster recovery times is positively influencing the market. Apart from this, key market players are extensively investing in research and development (R&D) activities to introduce SLENDER integrated delivery system (IDS) fixed-wire and DIRECT RX bioabsorbable rapid-exchange drug-eluting stent (DES) systems to treat coronary artery disease. They are also focusing on developing polymer-based stents, which is expected to bolster the growth of the market.

Key Market Segmentation:

Breakup by Biomaterial:

• Polymer-based Bioabsorbable Stents
• Metal-based Bioabsorbable Stents

Breakup by Absorption Rate:

• Slow-Absorption Stents
• Fast-Absorption Stents

Breakup by Application:

• Coronary Artery Disease
• Peripheral Artery Disease

Breakup by End User:

• Hospitals
• Cardiac Centers

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arterius Limited, B. Braun SE, Biotronik SE & Co. KG, Boston Scientific Corporation, Elixir Medical Corporation, Kyoto Medical Planning Co. Ltd., Lepu Medical Technology (Beijing) Co. Ltd., Meril Life Sciences Pvt. Ltd., Reva Medical LLC and Terumo Corporation.

Key Questions Answered in This Report

• 1.What was the size of the global bioabsorbable stents market in 2024?
• 2.What is the expected growth rate of the global bioabsorbable stents market during 2025-2033?
• 3.What are the key factors driving the global bioabsorbable stents market?
• 4.What has been the impact of COVID-19 on the global bioabsorbable stents market?
• 5.What is the breakup of the global bioabsorbable stents market based on the biomaterial?
• 6.What is the breakup of the global bioabsorbable stents market based on the absorption rate?
• 7.What is the breakup of the global bioabsorbable stents market based on the application?
• 8.What is the breakup of the global bioabsorbable stents market based on the end user?
• 9.What are the key regions in the global bioabsorbable stents market?
• 10.Who are the key players/companies in the global bioabsorbable stents market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Bioabsorbable Stents Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Biomaterial

• 6.1 Polymer-based Bioabsorbable Stents
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Metal-based Bioabsorbable Stents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Absorption Rate

• 7.1 Slow-Absorption Stents
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Fast-Absorption Stents
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Coronary Artery Disease
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Peripheral Artery Disease
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Cardiac Centers
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Arterius Limited
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 B. Braun SE
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Biotronik SE & Co. KG
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 SWOT Analysis
  • 15.3.5 Boston Scientific Corporation
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
    • 15.3.5.4 SWOT Analysis
  • 15.3.6 Elixir Medical Corporation
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Kyoto Medical Planning Co. Ltd.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Lepu Medical Technology (Beijing) Co. Ltd.
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
  • 15.3.9 Meril Life Sciences Pvt. Ltd.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Reva Medical LLC
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Terumo Corporation
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis